Article Dans Une Revue Infectious Diseases Now Année : 2025

Low-level primary clarithromycin resistance of Helicobacter pylori in Reunion Island

Résumé

Introduction: The increasing resistance of Helicobacter pylori to clarithromycin leads to an ongoing adaptation of empirical first-line treatment for H. pylori infections.
Patients and methods: Prospective study (2022-2023) of 364 patients with no previous treatment for H. pylori infection, addressed for gastroduodenal endoscopy to the University Hospital of Reunion Island.
Results: PCR tests (Allplex TM H. pylori & ClariRAssay, Seegene) performed on gastric biopsy samples detected H. pylori DNA in 100 samples (100/364; 27.5%) and mutations conferring resistance to clarithromycin in 10 of the positive samples (10/100; 10%). Prevalence of resistance determined by MICs (E-test method) was 41.2% for metronidazole, 13.2% for levofloxacin, 8.8% for clarithromycin. No resistance was detected for tetracycline, rifampicin, and amoxicillin.
Conclusion: The prevalence of primary clarithromycin-resistant H. pylori in Reunion Island is below 15%. Recommendation for the standard clarithromycin-based triple therapy as a first-line treatment can thus be maintained, even though antimicrobial susceptibility testing seems preferable.
Fichier principal
Vignette du fichier
1-s2.0-S2666991925000041-main.pdf (312) Télécharger le fichier
Origine Accord explicite pour ce dépôt

Dates et versions

hal-04900984 , version 1 (23-01-2025)

Identifiants

Citer

Arthur Charazac, Raphaël Delage, Maxime Pichon, Laure Kamus, Benoit Pichard, et al.. Low-level primary clarithromycin resistance of Helicobacter pylori in Reunion Island. Infectious Diseases Now, 2025, 55 (2), pp.105025. ⟨10.1016/j.idnow.2025.105025⟩. ⟨hal-04900984⟩
14 Consultations
0 Téléchargements

Altmetric

Partager

More